EA201890570A1 - [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль - Google Patents
[4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его сольInfo
- Publication number
- EA201890570A1 EA201890570A1 EA201890570A EA201890570A EA201890570A1 EA 201890570 A1 EA201890570 A1 EA 201890570A1 EA 201890570 A EA201890570 A EA 201890570A EA 201890570 A EA201890570 A EA 201890570A EA 201890570 A1 EA201890570 A1 EA 201890570A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- salt
- trimethyl
- oxo
- digidro
- penoxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- -1 ETHYLOXY COMPOUND Chemical class 0.000 title abstract 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015166247 | 2015-08-25 | ||
| PCT/JP2016/074863 WO2017034006A1 (ja) | 2015-08-25 | 2016-08-25 | ［４－（１，３，３－トリメチル－２－オキソ－３，４－ジヒドロ－１ｈ－キノキサリン－７－イル）フェノキシ］エチルオキシ化合物またはその塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890570A1 true EA201890570A1 (ru) | 2018-08-31 |
Family
ID=58100493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890570A EA201890570A1 (ru) | 2015-08-25 | 2016-08-25 | [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10189796B2 (https=) |
| EP (1) | EP3342768A4 (https=) |
| JP (2) | JP2017043614A (https=) |
| KR (1) | KR20180043329A (https=) |
| CN (1) | CN107922356A (https=) |
| CA (1) | CA2996278A1 (https=) |
| EA (1) | EA201890570A1 (https=) |
| HK (1) | HK1252159A1 (https=) |
| WO (1) | WO2017034006A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107922356A (zh) * | 2015-08-25 | 2018-04-17 | 参天制药株式会社 | [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐 |
| US20200121652A1 (en) | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| AR113967A1 (es) | 2017-12-18 | 2020-07-01 | Gruenenthal Gmbh | Pirrolidinamidas i sustituidas |
| TW201927769A (zh) | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ｉｉ |
| IL280212B2 (en) * | 2018-07-20 | 2023-09-01 | Gruenenthal Chemie | Transmuted triazoloquinoxaline histories |
| TWI811400B (zh) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之三唑并喹噁啉衍生物 |
| JP7446316B2 (ja) | 2019-01-11 | 2024-03-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換ピロリジンアミドｉｉｉ |
| EP3986885B1 (en) | 2019-06-19 | 2023-05-03 | Grünenthal GmbH | Substituted pyrrolidine amides iv |
| EP3986886A2 (en) | 2019-06-19 | 2022-04-27 | Grünenthal GmbH | Substituted pyrrolidine amides v |
| ES3025970T3 (en) * | 2020-01-17 | 2025-06-10 | Gruenenthal Gmbh | Quinoxaline derivatives as modulators of the glucocorticoid receptor |
| WO2021144439A1 (en) * | 2020-01-17 | 2021-07-22 | Grünenthal GmbH | Quinoxaline derivatives |
| WO2022008705A1 (en) | 2020-07-09 | 2022-01-13 | Grünenthal GmbH | Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60113032T2 (de) | 2000-10-30 | 2006-07-06 | Pfizer Products Inc., Groton | Glukokortikoidrezeptor-Modulatoren |
| EP1995242B1 (en) * | 2006-03-14 | 2012-11-07 | Santen Pharmaceutical Co., Ltd | Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
| JP5054996B2 (ja) | 2006-03-14 | 2012-10-24 | 参天製薬株式会社 | グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体 |
| ES2419239T3 (es) * | 2007-05-29 | 2013-08-20 | Santen Pharmaceutical Co., Ltd | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene como sustituyente un grupo fenilo con una estructura de éster de ácido sulfónico o una estructura de amida de ácido sulfónico introducida en el mismo y que tienen una actividad de unión al receptor de glucocorticoides |
| JP2009084274A (ja) | 2007-09-13 | 2009-04-23 | Santen Pharmaceut Co Ltd | 新規１，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体 |
| WO2009035067A1 (ja) * | 2007-09-13 | 2009-03-19 | Santen Pharmaceutical Co., Ltd. | １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト |
| KR20110010634A (ko) | 2008-05-12 | 2011-02-01 | 산텐 세이야꾸 가부시키가이샤 | 치환 옥시기를 가지는 2,2,4-트리메틸-6-페닐-1,2-디하이드로퀴놀린 유도체를 포함하는 글루코코르티코이드 수용체 작용제 |
| WO2010029986A1 (ja) * | 2008-09-12 | 2010-03-18 | 参天製薬株式会社 | スルホン酸エステル構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体からなるグルココルチコイド受容体アゴニスト |
| CN107922356A (zh) * | 2015-08-25 | 2018-04-17 | 参天制药株式会社 | [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐 |
-
2016
- 2016-08-25 CN CN201680049254.XA patent/CN107922356A/zh active Pending
- 2016-08-25 HK HK18111552.7A patent/HK1252159A1/zh unknown
- 2016-08-25 US US15/753,410 patent/US10189796B2/en active Active
- 2016-08-25 WO PCT/JP2016/074863 patent/WO2017034006A1/ja not_active Ceased
- 2016-08-25 JP JP2016164830A patent/JP2017043614A/ja active Pending
- 2016-08-25 EP EP16839353.6A patent/EP3342768A4/en not_active Withdrawn
- 2016-08-25 EA EA201890570A patent/EA201890570A1/ru unknown
- 2016-08-25 CA CA2996278A patent/CA2996278A1/en not_active Abandoned
- 2016-08-25 KR KR1020187008105A patent/KR20180043329A/ko not_active Ceased
-
2018
- 2018-12-05 US US16/210,163 patent/US10435379B2/en not_active Expired - Fee Related
-
2019
- 2019-08-06 US US16/532,533 patent/US20190359577A1/en not_active Abandoned
-
2021
- 2021-05-28 JP JP2021089664A patent/JP7037687B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20190106393A1 (en) | 2019-04-11 |
| KR20180043329A (ko) | 2018-04-27 |
| JP2017043614A (ja) | 2017-03-02 |
| US10435379B2 (en) | 2019-10-08 |
| WO2017034006A1 (ja) | 2017-03-02 |
| JP2021138728A (ja) | 2021-09-16 |
| CN107922356A (zh) | 2018-04-17 |
| US20180244633A1 (en) | 2018-08-30 |
| HK1252159A1 (zh) | 2019-05-17 |
| JP7037687B2 (ja) | 2022-03-16 |
| US20190359577A1 (en) | 2019-11-28 |
| US10189796B2 (en) | 2019-01-29 |
| EP3342768A4 (en) | 2019-01-23 |
| CA2996278A1 (en) | 2017-03-02 |
| EP3342768A1 (en) | 2018-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890570A1 (ru) | [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
| EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
| MX373549B (es) | Derivado de pirazol amida. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201590562A1 (ru) | Бензамиды | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 |